Intravitreal bevacizumab treatment reduces ocular blood flow in retinopathy of prematurity: a four-case report

Matsumoto, Tadashi; Itokawa, Takashi; Shiba, Tomoaki; Tomita, Masahiko; Hine, Kotaro; Mizukaki, Norio; Yoda, Hitoshi; Hori, Yuichi

doi:10.1007/s00417-018-4063-0

Cited by 7 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 Using laser speckle flowgraphy imaging, a technique that requires sedation and pharmacological mydriasis, intravitreal bevacizumab was found to result in decreased venous dilation, arterial tortuosity, and overall ocular blood flow in four preterm infants from Japan. 24 The same group had previously also found reduced ocular blood flow in five infants after laser ablation. 25 Taken together, these data suggest that increased retinal blood flow is a hallmark of ROP with plus disease, which increases during progression of the disease and leads to arterial tortuosity, akin to what can be observed in a free-lying garden hose when the faucet is turned on further.…”

Section: Discussionmentioning

confidence: 83%

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Mohr

Fischer

Czernik

et al. 2023

European Journal of Ophthalmology

View full text Add to dashboard Cite

Background/Objectives Progression of retinopathy of prematurity (ROP) is associated with increased retinal blood flow velocities. We investigated changes of central retinal arterial and venous blood flow after intravitreal administration of bevacizumab. Subjects/Methods Prospective observational study using serial ultrasound Doppler imaging in preterm infants with bevacizumab-treated ROP. Eyes were examined 1 [0–2] days before injection (median [interquartile range]), and at three time points after injection (1 [1–2] days, 6 [3–8] days, and 17 [9–28] days). Preterm infants with ROP stage 2 displaying spontaneous regression served as controls. Results In 21 eyes of 12 infants with bevacizumab-treated ROP, peak arterial systolic velocity declined from 13.6 [11.0-16.3] cm/s prior to intravitreal bevacizumab to 11.2 [9.4–13.9] cm/s, 10.6 [9.2–13.3] cm/s and 9.3 [8.2–11.0] cm/s at discharge ( p = .002). There was also a decline of the arterial velocity time integral (from 3.1 [2.3–3.9] cm to 2.9 [2.4–3.5], 2.7 [2.3–3.2] cm and 2.2 [2.0–2.7], p = .021) and mean velocity in the central retinal vein (from 4.5 [3.6–5.8] cm/s to 3.7 [2.6–4.1] cm/s, 3.5 [3.0–4.3] cm/s, and 3.2 [2.8–4.6] cm/s, p = .012). Arterial end-diastolic velocity and resistance index remained unchanged. Blood flow velocities in bevacizumab-treated eyes examined before injection were significantly higher than those measured in untreated eyes that ultimately showed spontaneous regression of ROP. Sequential examinations in these controls did not reveal any declines of retinal blood flow velocities. Conclusion Increased retinal arterial and venous blood flow velocities in infants with threshold ROP decline following intravitreal bevacizumab injection.

show abstract

Section: Discussionmentioning

confidence: 83%

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Mohr

Fischer

Czernik

et al. 2023

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“… 29 Laser speckle contrast imaging has also been previously used to show that blood flow reduces significantly after treatment for ROP via laser photocoagulation or with intravitreal delivery of bevacizumab. 30 , 31 , 32 …”

Section: Discussionmentioning

confidence: 99%

Association of Speckle-Based Blood Flow Measurements and Fluorescein Angiography in Infants with Retinopathy of Prematurity

Shats,

Balasubramanian,

Sidelnikov

et al. 2024

Ophthalmology Science

View full text Add to dashboard Cite

“…Vasodilators such as VEGF increase the incidence of early age-related macular degeneration by 70% [57]. Retinal blood flow is increased in the proliferative phase of OIR and retinopathy of prematurity [65][66][67][68] and in the progression of choroidal neovascularization [69,70]. Hence, chronic vasodilation is associated with the development of pathological neovascularization.…”

Section: Plos Onementioning

confidence: 99%

Peptide Lv augments intermediate-conductance calcium-dependent potassium channels (KCa3.1) in endothelial cells to promote angiogenesis

Pham

Niemi²,

Ko³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Peptide Lv is a small endogenous secretory peptide that is expressed in various tissues and conserved across different species. Patients with diabetic retinopathy, an ocular disease with pathological angiogenesis, have upregulated peptide Lv in their retinas. The pro-angiogenic activity of peptide Lv is in part through promoting vascular endothelial cell (EC) proliferation, migration, and sprouting, but its molecular mechanism is not completely understood. This study aimed to decipher how peptide Lv promotes EC-dependent angiogenesis by using patch-clamp electrophysiological recordings, Western immunoblotting, quantitative PCR, and cell proliferation assays in cultured ECs. Endothelial cells treated with peptide Lv became significantly hyperpolarized, an essential step for EC activation. Treatment with peptide Lv augmented the expression and current densities of the intermediate-conductance calcium-dependent potassium (KCa3.1) channels that contribute to EC hyperpolarization but did not augment other potassium channels. Blocking KCa3.1 attenuated peptide Lv-elicited EC proliferation. These results indicate that peptide Lv-stimulated increases of functional KCa3.1 in ECs contributes to EC activation and EC-dependent angiogenesis.

show abstract

Intravitreal bevacizumab treatment reduces ocular blood flow in retinopathy of prematurity: a four-case report

Abstract: IVB improves vein dilation and artery tortuosity, while reducing ocular blood flow in neonates with ROP. We suggest that neovascularization might not be involved in reducing ocular blood flow in the early stage of IVB treatment.

Cited by 7 publications

References 32 publications

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Association of Speckle-Based Blood Flow Measurements and Fluorescein Angiography in Infants with Retinopathy of Prematurity

Peptide Lv augments intermediate-conductance calcium-dependent potassium channels (KCa3.1) in endothelial cells to promote angiogenesis

Contact Info

Product

Resources

About